Intarcia Therapeutics, Inc. a privately held biopharmaceutical company announced that the Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for ITCA 650 (exenatide implant) for the treatment of type 2 diabetes. The FDA is requesting that they resubmit with simplified procedures this Feb. 2018. The company looks forward to meeting with the FDA and working closely together on next steps. Intarcia does not anticipate the need to conduct new pivotal trials or any long lead-time CMC activities in order to satisfy the requirements of the FDA.